Artelo Biosciences, Inc. (ARTL) stock rose 15.77 percent to $5.14, gaining $0.70 on Monday, following the publication of new research supporting its non-opioid pain therapy approach.
The stock is currently trading at $5.14, compared to its previous close of $4.44 on the Nasdaq. During the session, it reached a high of $5.64 and a low of $4.79, with trading volume climbing to 29,255,913 shares, well above its average volume of 2,882,845.
The move comes after the company announced a peer-reviewed article highlighting FABP5 as a promising therapeutic target for pain management. Preclinical data showed consistent analgesic effects across multiple pain models, supporting the potential of its candidate ART26.12 as a novel, non-opioid treatment. Artelo Biosciences' 52-week range is $2.95 to $85.80.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.